Thyroid Cancer | Tumor

Gavreto Approved by FDA to Treat Thyroid Cancer

December 1st 2020, 8:36pm

Article

The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

Thyroid Cancer Awareness Month: What You Need to Know

September 21st 2019, 8:00pm

Article

For Thyroid Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

New Therapies Making Progress in Rare Cancers

September 5th 2019, 7:00pm

Article

Progress in treating rare cancers represents the most significant oncology advance of last year, ASCO says.

Blowing a Fuse: Fighting NTRK Gene Fusions in Cancer

August 30th 2019, 12:00am

Article

A new drug can break the circuit of cancer-causing effects that develop when certain genes fuse.

Cancer: It's Never An Easy Journey

July 2nd 2019, 6:00pm

Article

Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.

Friday Frontline: June 7, 2019

June 7th 2019, 10:00pm

Article

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

Diagnosed, Not Defeated

May 23rd 2019, 12:21am

Article

As a result of what I went through and my never-ending passion for helping others, I believe that my diagnosis happened for a reason – to lead me to a career in patient advocacy.

Sweet Serendipity: Cancer Caught on Television

November 27th 2018, 8:46pm

Article

Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.

LOXO-292 Granted Breakthrough Designation for Thyroid Cancer

October 15th 2018, 7:06pm

Article

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

LOXO-292 Granted Breakthrough Therapy Designation for Lung and Thyroid Cancer

September 5th 2018, 9:37pm

Article

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

x